MX384234B - Uso de pridopidina para el tratamiento de enfermedad de huntington. - Google Patents
Uso de pridopidina para el tratamiento de enfermedad de huntington.Info
- Publication number
- MX384234B MX384234B MX2015017307A MX2015017307A MX384234B MX 384234 B MX384234 B MX 384234B MX 2015017307 A MX2015017307 A MX 2015017307A MX 2015017307 A MX2015017307 A MX 2015017307A MX 384234 B MX384234 B MX 384234B
- Authority
- MX
- Mexico
- Prior art keywords
- pridopidine
- huntington
- disease
- patient
- treatment
- Prior art date
Links
- YGKUEOZJFIXDGI-UHFFFAOYSA-N pridopidine Chemical compound C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGKUEOZJFIXDGI-UHFFFAOYSA-N 0.000 title abstract 4
- 229950003764 pridopidine Drugs 0.000 title abstract 4
- 208000023105 Huntington disease Diseases 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- YGRHOYQMBLLGEV-UHFFFAOYSA-N 4-(3-methylsulfonylphenyl)-1-propylpiperidine;hydrochloride Chemical compound Cl.C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGRHOYQMBLLGEV-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361837928P | 2013-06-21 | 2013-06-21 | |
| US201361877832P | 2013-09-13 | 2013-09-13 | |
| PCT/US2014/043204 WO2014205229A1 (en) | 2013-06-21 | 2014-06-19 | Use of high dose pridopidine for treating huntington's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015017307A MX2015017307A (es) | 2016-08-03 |
| MX384234B true MX384234B (es) | 2025-03-14 |
Family
ID=52105289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015017307A MX384234B (es) | 2013-06-21 | 2014-06-19 | Uso de pridopidina para el tratamiento de enfermedad de huntington. |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US10322119B2 (enExample) |
| EP (1) | EP3010506B1 (enExample) |
| JP (1) | JP2016523862A (enExample) |
| KR (1) | KR102316933B1 (enExample) |
| CN (1) | CN105592848A (enExample) |
| AU (1) | AU2014281414A1 (enExample) |
| BR (1) | BR112015029918A2 (enExample) |
| CA (1) | CA2913781C (enExample) |
| CL (1) | CL2015003690A1 (enExample) |
| DK (1) | DK3010506T3 (enExample) |
| EA (1) | EA201690069A1 (enExample) |
| ES (1) | ES2879631T3 (enExample) |
| HK (1) | HK1221646A1 (enExample) |
| HU (1) | HUE054783T2 (enExample) |
| IL (1) | IL242804B (enExample) |
| MX (1) | MX384234B (enExample) |
| PE (2) | PE20160195A1 (enExample) |
| PH (1) | PH12015502691A1 (enExample) |
| PL (1) | PL3010506T3 (enExample) |
| SG (1) | SG11201509729YA (enExample) |
| TW (1) | TW201529069A (enExample) |
| UA (1) | UA122999C2 (enExample) |
| UY (1) | UY35624A (enExample) |
| WO (1) | WO2014205229A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| PH12013500406A1 (en) | 2010-09-03 | 2019-07-17 | Teva Pharmaceuticals Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| US9012476B2 (en) | 2011-12-08 | 2015-04-21 | IVAX International GmbH | Hydrobromide salt of pridopidine |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| CN106170287A (zh) * | 2014-01-22 | 2016-11-30 | 梯瓦制药国际有限责任公司 | 改进释放的普利多匹定制剂 |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| CA2970799A1 (en) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
| US11471449B2 (en) * | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| HUE060353T2 (hu) | 2015-02-25 | 2023-02-28 | Prilenia Neurotherapeutics Ltd | Pridopidin alkalmazása memória javítására |
| US20170020854A1 (en) * | 2015-07-22 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Pridopidine base formulations and their use |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| PL3419622T3 (pl) | 2016-02-24 | 2024-07-08 | Prilenia Neurotherapeutics Ltd. | Leczenie neurodegeneracyjnej choroby oczu przy użyciu pridopidyny |
| WO2018039477A1 (en) * | 2016-08-24 | 2018-03-01 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for treating functional decline |
| JP7278210B2 (ja) * | 2016-08-24 | 2023-05-19 | プリレニア ニューロセラピューティクス リミテッド | ジストニアを治療するためのプリドピジンの使用 |
| US20200375966A1 (en) * | 2016-09-15 | 2020-12-03 | Prilenia Therapeutics Development Ltd | Use of pridopidine for the treatment of anxiety and depression |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| DK4005570T3 (da) | 2016-09-16 | 2024-08-19 | Prilenia Neurotherapeutics Ltd | Pridopidin til anvendelse behandling af retts syndroe |
| AU2018210145B2 (en) | 2017-01-20 | 2023-06-29 | Agency For Science, Technology And Research | Use of pridopidine for the treatment of fragile X syndrome |
| EP3668509B1 (en) * | 2017-08-14 | 2022-11-16 | Prilenia Neurotherapeutics Ltd. | Method of treating amyotrophic lateral sclerosis with pridopidine |
| JP2020532517A (ja) * | 2017-08-30 | 2020-11-12 | プリレニア ニューロセラピューティクス リミテッド | 高濃度プリドピジン製剤 |
| BR112020004622A2 (pt) | 2017-09-08 | 2020-09-24 | Prilenia Neurotherapeutics Ltd. | pridopidina para tratamento de discinesias induzidas por droga |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| CN113365551A (zh) * | 2019-01-31 | 2021-09-07 | 豪夫迈·罗氏有限公司 | 评估亨廷顿氏病的进展 |
| WO2020161707A1 (en) | 2019-02-04 | 2020-08-13 | Prilenia Neurotherapeutics Ltd. | Low dose pridopidine for parkinson's disease and other diseases associated with parkinsonism |
| JP7436524B2 (ja) * | 2019-06-12 | 2024-02-21 | プリレニア ニューロセラピューティクス リミテッド | ハンチントン病及びその症状を治療するためのプリドピジン及びその類似体を含む組成物 |
| WO2021055443A1 (en) * | 2019-09-17 | 2021-03-25 | Hoffmann-La Roche Inc. | Improvements in personalized healthcare for patients with movement disorders |
| WO2022094565A1 (en) * | 2020-10-28 | 2022-05-05 | Buck Institute For Research On Aging | N-propargylglycine: a unique inhibitor of proline dehydrogenase with brain-enhancing mitohormesis properties capable of mitigating neurodegenerative disorders |
| WO2025181805A1 (en) * | 2024-02-27 | 2025-09-04 | Prilenia Neurotherapeutics Ltd. | Pridopidine and sigma 2 antagonist agent for treating huntington disease and symptoms thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| WO2005053703A1 (en) | 2003-12-02 | 2005-06-16 | Leslie James Sheldon | Combination therapy for dementia, depression and apathy |
| JP4891908B2 (ja) | 2004-10-13 | 2012-03-07 | エヌエスエービー，フィリアル アフ ニューロサーチ スウェーデン アクチボラゲット，スヴェリエ | ４−（３−メタンスルホニルフェニル）−１−ｎ−プロピルピペリジンの合成方法 |
| EP1815857A1 (en) | 2006-02-02 | 2007-08-08 | LEK Pharmaceuticals D.D. | A pharmaceutical composition comprising perindopril |
| EP2146961B1 (en) | 2007-04-12 | 2014-01-29 | IVAX International GmbH | N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles |
| WO2010008486A2 (en) | 2008-06-24 | 2010-01-21 | Parkinsons Institute | Pluripotent cell lines and methods of use thereof |
| US8384755B2 (en) | 2009-08-26 | 2013-02-26 | Intouch Technologies, Inc. | Portable remote presence robot |
| US20110206782A1 (en) | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
| WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| PH12013500406A1 (en) | 2010-09-03 | 2019-07-17 | Teva Pharmaceuticals Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| CN103958469B (zh) * | 2011-09-07 | 2016-04-20 | 梯瓦制药国际有限责任公司 | 一种新的普利多匹定盐酸盐多晶型形态 |
| US9012476B2 (en) * | 2011-12-08 | 2015-04-21 | IVAX International GmbH | Hydrobromide salt of pridopidine |
| US9744155B2 (en) | 2012-03-28 | 2017-08-29 | Ixcela, Inc. | IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk |
| US20130267552A1 (en) | 2012-04-04 | 2013-10-10 | IVAX International GmbH | Pharmaceutical compositions for combination therapy |
| EP2900330A4 (en) | 2012-09-27 | 2016-05-25 | Teva Pharma | LAQUINIMOD AND PRIDOPIDINE FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES |
| US20150216850A1 (en) | 2012-09-27 | 2015-08-06 | Michael Hayden | Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease |
| CN106170287A (zh) | 2014-01-22 | 2016-11-30 | 梯瓦制药国际有限责任公司 | 改进释放的普利多匹定制剂 |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| CA2970799A1 (en) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
| HUE060353T2 (hu) | 2015-02-25 | 2023-02-28 | Prilenia Neurotherapeutics Ltd | Pridopidin alkalmazása memória javítására |
| WO2016138135A1 (en) | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Sigma-1 receptor modulators for treating huntington's disease |
| US20170020854A1 (en) | 2015-07-22 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Pridopidine base formulations and their use |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| WO2017048457A1 (en) | 2015-09-18 | 2017-03-23 | Teva Pharmaceuticals Industries Ltd. | Combination of laquinimod and pridopidine to treat multiple sclerosis |
| WO2018039477A1 (en) | 2016-08-24 | 2018-03-01 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for treating functional decline |
| JP7278210B2 (ja) | 2016-08-24 | 2023-05-19 | プリレニア ニューロセラピューティクス リミテッド | ジストニアを治療するためのプリドピジンの使用 |
| US20200375966A1 (en) | 2016-09-15 | 2020-12-03 | Prilenia Therapeutics Development Ltd | Use of pridopidine for the treatment of anxiety and depression |
| DK4005570T3 (da) | 2016-09-16 | 2024-08-19 | Prilenia Neurotherapeutics Ltd | Pridopidin til anvendelse behandling af retts syndroe |
| WO2018053275A1 (en) | 2016-09-16 | 2018-03-22 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for the treatment of familial dysautonomia |
-
2014
- 2014-06-19 EP EP14813621.1A patent/EP3010506B1/en active Active
- 2014-06-19 SG SG11201509729YA patent/SG11201509729YA/en unknown
- 2014-06-19 CA CA2913781A patent/CA2913781C/en active Active
- 2014-06-19 WO PCT/US2014/043204 patent/WO2014205229A1/en not_active Ceased
- 2014-06-19 EA EA201690069A patent/EA201690069A1/ru unknown
- 2014-06-19 MX MX2015017307A patent/MX384234B/es unknown
- 2014-06-19 CN CN201480035525.7A patent/CN105592848A/zh active Pending
- 2014-06-19 US US14/309,111 patent/US10322119B2/en active Active
- 2014-06-19 ES ES14813621T patent/ES2879631T3/es active Active
- 2014-06-19 UA UAA201600462A patent/UA122999C2/uk unknown
- 2014-06-19 JP JP2016521580A patent/JP2016523862A/ja not_active Withdrawn
- 2014-06-19 HU HUE14813621A patent/HUE054783T2/hu unknown
- 2014-06-19 AU AU2014281414A patent/AU2014281414A1/en not_active Abandoned
- 2014-06-19 PE PE2015002618A patent/PE20160195A1/es not_active Application Discontinuation
- 2014-06-19 KR KR1020167001531A patent/KR102316933B1/ko active Active
- 2014-06-19 PE PE2016002253A patent/PE20170302A1/es not_active Application Discontinuation
- 2014-06-19 DK DK14813621.1T patent/DK3010506T3/da active
- 2014-06-19 PL PL14813621T patent/PL3010506T3/pl unknown
- 2014-06-19 BR BR112015029918A patent/BR112015029918A2/pt not_active Application Discontinuation
- 2014-06-19 HK HK16109788.9A patent/HK1221646A1/zh unknown
- 2014-06-20 TW TW103121433A patent/TW201529069A/zh unknown
- 2014-06-23 UY UY35624A patent/UY35624A/es not_active Application Discontinuation
-
2015
- 2015-11-26 IL IL242804A patent/IL242804B/en unknown
- 2015-12-02 PH PH12015502691A patent/PH12015502691A1/en unknown
- 2015-12-21 CL CL2015003690A patent/CL2015003690A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UA122999C2 (uk) | 2021-02-03 |
| HUE054783T2 (hu) | 2021-09-28 |
| JP2016523862A (ja) | 2016-08-12 |
| US20140378508A1 (en) | 2014-12-25 |
| EP3010506A1 (en) | 2016-04-27 |
| WO2014205229A8 (en) | 2015-04-09 |
| EA201690069A1 (ru) | 2016-06-30 |
| UY35624A (es) | 2015-01-30 |
| AU2014281414A1 (en) | 2016-01-21 |
| SG11201509729YA (en) | 2015-12-30 |
| CL2015003690A1 (es) | 2016-10-28 |
| DK3010506T3 (da) | 2021-07-12 |
| EP3010506B1 (en) | 2021-05-12 |
| ES2879631T3 (es) | 2021-11-22 |
| WO2014205229A1 (en) | 2014-12-24 |
| MX2015017307A (es) | 2016-08-03 |
| IL242804B (en) | 2022-02-01 |
| CN105592848A (zh) | 2016-05-18 |
| PH12015502691A1 (en) | 2016-03-14 |
| US10322119B2 (en) | 2019-06-18 |
| PE20170302A1 (es) | 2017-03-31 |
| PE20160195A1 (es) | 2016-05-14 |
| HK1221646A1 (zh) | 2017-06-09 |
| CA2913781C (en) | 2022-05-10 |
| TW201529069A (zh) | 2015-08-01 |
| EP3010506A4 (en) | 2017-02-08 |
| KR20160055122A (ko) | 2016-05-17 |
| CA2913781A1 (en) | 2014-12-24 |
| PL3010506T3 (pl) | 2021-11-02 |
| KR102316933B1 (ko) | 2021-10-26 |
| BR112015029918A2 (pt) | 2017-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX384234B (es) | Uso de pridopidina para el tratamiento de enfermedad de huntington. | |
| MX390627B (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
| MX2024010140A (es) | Nuevos metodos. | |
| PH12015502628B1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
| MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
| MX377576B (es) | Formulaciones de pridopidina de liberación modificada. | |
| BR112015018168A2 (pt) | inibidores de rock suaves | |
| MX378579B (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
| BR112012022064A2 (pt) | tratamento de artrite lúpica usando laquinimod | |
| MX2015016421A (es) | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. | |
| PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| EA201691058A1 (ru) | Производные пирролопирролона и их применение для лечения заболеваний | |
| MX381440B (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
| PH12016502352A1 (en) | Pharmaceutical composition | |
| TW201613578A (en) | Pharmaceutical combinations | |
| NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
| BR112014030288A8 (pt) | composição farmacêutica, uso da mesma, e, uso de metanossulfonilacetonitrila | |
| BR112015031835A8 (pt) | agentes terapêuticos, combinação dos referidos agentes e agente terapêutico adicional, uso dos referidos agentes e da referida combinação para fabricação de medicamento para a profilaxia e/ou tratamento de distúrbios do movimento hipercinético | |
| EA202090416A1 (ru) | Способы лечения симптомов гастропареза с использованием велусетрага | |
| MX385725B (es) | Composición farmacéutica que comprende sumatriptán para tratamiento de migraña. | |
| EA201990553A1 (ru) | Применение придопидина для лечения ухудшения функциональной способности | |
| AR096674A1 (es) | Método de tratamiento de un paciente humano que sufre de la enfermedad de huntington | |
| CY1117605T1 (el) | Θεραπεια της ασθενειας crohn me laquinimod | |
| AR103764A1 (es) | Pridopidina como mejoradora de la función cognitiva y en el tratamiento de la enfermedad de alzheimer |